TriangleNCT04478123 · OUTCOME
Number of Days Post HDT-AHCT Requiring Transfusions or Grade 4 CTCAE Thrombocytopenia
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- days
- Interval / dispersion
- Full Range
- Time frame
- up to 42 days
What was measured
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.
Groups in this outcome
Romiplostim
Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.
| Group | Source count |
|---|---|
| Romiplostim | 59 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Romiplostim | 6 | Not reported | 0 | 17 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 17
- value
- 6
- denoms
- counts
- group Id
- OG000
- value
- 59
- units
- Participants
- description
- Common Terminology Criteria for Adverse Events (CTCAE) Version 5.
- dispersion Type
- Full Range
- groups
- description
- Patients will be enrolled prior to admission for High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT), and they will undergo their planned HDT-AHCT for their respective hematologic malignancy as per institutional standards.
- id
- OG000
- title
- Romiplostim
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- up to 42 days
- title
- Number of Days Post HDT-AHCT Requiring Transfusions or Grade 4 CTCAE Thrombocytopenia
- type
- PRIMARY
- unit Of Measure
- days
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice